Equillium reports third quarter 2023 financial results and provides corporate and clinical updates

La jolla, calif.--(business wire)---- $eq--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2023 and provided corporate and clinical development updates. “the third quarter was focused on clinical execution and expanding education on our multi-cytokine platform and clinical programs ahead of init.
EQ Ratings Summary
EQ Quant Ranking